Skip to main content
Jeffrey Jones, MD, Oncology, Cambridge, MA, St. Mary's Medical Center

JeffreyA.JonesMDMPH MBA

Oncology Cambridge, MA

Hematologic Oncology

Chief Medical Officer Cullinan Oncology

Dr. Jones is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jones' full profile

Already have an account?

Education & Training

  • Ohio State University Fisher College of Business
    Ohio State University Fisher College of BusinessMBA, 2015 - 2017
  • University of Texas School of Public Health
    University of Texas School of Public HealthMPH, 2004 - 2006
  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 2000

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2018 - 2025
  • NJ State Medical License
    NJ State Medical License 2017 - 2023
  • OH State Medical License
    OH State Medical License 2006 - 2018

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical Trials  
    Steven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
  • Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia  
    Jeffrey A Jones, William Wierda, Clinical Cancer Research

Press Mentions

  • Shop Talk
    Shop TalkNovember 25th, 2017
  • Idelalisib Use Expands with New CLL Indication Pending
    Idelalisib Use Expands with New CLL Indication PendingJuly 30th, 2015
  • REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsAugust 6th, 2023

Professional Memberships

Hospital Affiliations